Main Subjects = Medicinal chemistry and drug design
Number of Articles: 18
AN INSIGHT INTO MEDICINAL PROPERTIES OF QUINOXALINE SCAFFOLD, WITH A FOCUS ON THEIR ANTICANCER POTENTIAL AS INTERCALATING AGENTS

Volume 70, Issue 2, September 2024, Pages 54-73

Mohammed A Dahab; Mohammed Abdel Hamid; Ibrahim Eissaa; Mohammed Mohammed

INSIGHTS INTO MOLECULAR GLUE DEGRADERS: A REVIEW

Volume 70, Issue 2, September 2024, Pages 74-102

Mohamed Ayman ALy El-Zahabi; Abdullah El-Nagar; Hazem Elkady

AN INSIGHT ON MEDICINAL ATTRIBUTES OF PHTHALAZINE SCAFFOLD, WITH A FOCUS ON THEIR ANTICANCER PROPERTIES AS VEGFR-2 INHIBITORS

Volume 69, Issue 1, March 2024, Pages 25-37

Mohammed A Dahab; Hatem B Bayoumi; Fathalla Khedr; Mohamed K Ibrahim

DUAL INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) AND TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AS ANTI-TUMOR IMMUNE MODULATORS

Volume 69, Issue 1, March 2024, Pages 38-61

Mohamed Ayman ALy El-Zahabi; Mostafa Youssef Abouzeid; Ibrahim H Eissa; Mohamed S Taghour

PYRAZOLOPYRIMIDINES AS ANTICANCER AGENTS; SYNTHESES AND MODE OF ACTION (REVIEW ARTICLE)

Volume 69, Issue 1, March 2024, Pages 62-107

Wafaa Zaghary; Tamer Nasr; Rania Abd El-Hameed; Tamer M Sakr; Dina Adel Osman; Khaled El-Adl

PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS

Volume 68, Issue 2, September 2023, Pages 64-81

Mohamed Ayman ALy El-Zahabi; Reda G Yousef; Ibrahim H Eissa; Alaa Elwan

EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS

Volume 68, Issue 2, September 2023, Pages 82-110

Abdelsalam Mohamed Ouf; Adel A Marzouk; Montaser A Shykhoon; Mohamed Ayman ALy El-Zahabi

VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS

Volume 68, Issue 2, September 2023, Pages 111-129

Helmy Sakr; Islam Otify; Rezk R Ayyad; Alaa Elwan

AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS

Volume 68, Issue 2, September 2023, Pages 130-158

Mostafa Mohammed Aref; Abeer A Mohamed; Mohammed A Dahab; Mohamed Ayman ALy El-Zahabi

REVIEW ON THE SIGNIFICANCE OF PYRIMIDINE DERIVATIVES AS POTENT ANTI-ANGIOGENIC VEGFR-2 INHIBITORS

Volume 67, Issue 1, March and April 2023, Pages 37-50

ibrahim issa; Abdulrahman Saleh; Mohamed Khalifa; Hazem Mahdy

RECENT ADVANCES ON PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS.

Volume 67, Issue 1, March and April 2023, Pages 51-67

Hazem Mahdy; Hany Elnagar; Helmy Sakr

PIM KINASES INHIBITORS AND PYRIMIDINE-BASED ANTICANCER AGENTS

Volume 67, Issue 1, March and April 2023, Pages 68-83

ibrahim issa; Ahmed Hammam; Helmy Sakr; Rezk Ayyad

RECENT ADVANCES IN DRUGS TARGETING PROTEIN KINASES FOR CANCER THERAPY.

Volume 66, Issue 2, September and October 2022, Pages 56-86

Hazem Mahdy; Mahmoud Shaat; rezk Ayyad

Al-Azhar Journal of Pharmaceutical Sciences

Journal Archive